172 related articles for article (PubMed ID: 12084189)
1. Permanent seed implantation for localized adenocarcinoma of the prostate.
Stone NN; Stock RG
Curr Urol Rep; 2002 Jun; 3(3):201-6. PubMed ID: 12084189
[TBL] [Abstract][Full Text] [Related]
2. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
Kollmeier MA; Stock RG; Stone N
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
[TBL] [Abstract][Full Text] [Related]
3. Prostate brachytherapy: treatment strategies.
Stone NN; Stock RG
J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
[TBL] [Abstract][Full Text] [Related]
4. Erectile function after permanent prostate brachytherapy.
Merrick GS; Butler WM; Galbreath RW; Stipetich RL; Abel LJ; Lief JH
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(4):893-902. PubMed ID: 11958881
[TBL] [Abstract][Full Text] [Related]
5. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
Merrick GS; Butler WM; Galbreath RW; Lief JH
Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
[TBL] [Abstract][Full Text] [Related]
6. Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: outcomes of 1300 patients.
Yorozu A; Kuroiwa N; Takahashi A; Toya K; Saito S; Nishiyama T; Yagi Y; Tanaka T; Shiraishi Y; Ohashi T
Brachytherapy; 2015; 14(2):111-7. PubMed ID: 25127123
[TBL] [Abstract][Full Text] [Related]
7. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
[TBL] [Abstract][Full Text] [Related]
8. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
9. High dose rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds.
Grills IS; Martinez AA; Hollander M; Huang R; Goldman K; Chen PY; Gustafson GS
J Urol; 2004 Mar; 171(3):1098-104. PubMed ID: 14767279
[TBL] [Abstract][Full Text] [Related]
10. A comparison of radiation dose to the bulb of the penis in men with and without prostate brachytherapy-induced erectile dysfunction.
Merrick GS; Wallner K; Butler WM; Galbreath RW; Lief JH; Benson ML
Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):597-604. PubMed ID: 11395225
[TBL] [Abstract][Full Text] [Related]
11. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
12. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
13. [Curative radiotherapy of localized prostate cancer. Treatment methods and results].
Schwarz R
Urologe A; 2003 Sep; 42(9):1212-20. PubMed ID: 14504754
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study combining low dose rate (192)Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma.
Nickers P; Coppers L; Beauduin M; Darimont M; de Leval J; Deneufbourg J
Radiother Oncol; 2000 Apr; 55(1):41-7. PubMed ID: 10788687
[TBL] [Abstract][Full Text] [Related]
15. Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate.
Lawton CA; Yan Y; Lee WR; Gillin M; Firat S; Baikadi M; Crook J; Kuettel M; Morton G; Sandler H
Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):e795-801. PubMed ID: 22330999
[TBL] [Abstract][Full Text] [Related]
16. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials.
Ghaly M; Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1288-93. PubMed ID: 12654439
[TBL] [Abstract][Full Text] [Related]
17. Correlation between real-time intraoperative and postoperative dosimetry and its implications on intraoperative planning.
Yan C; Huq MS; Heron DE; Beriwal S; Wynn RB
Brachytherapy; 2019; 18(3):338-347. PubMed ID: 30655047
[TBL] [Abstract][Full Text] [Related]
18. Live implant dosimetry may be an effective replacement for postimplant computed tomography in localized prostate cancer patients receiving low dose rate brachytherapy.
Roshan D; Joyce K; Woulfe P; Gorakati PR; Stock R; Sullivan FJ
Brachytherapy; 2021; 20(4):873-882. PubMed ID: 33840634
[TBL] [Abstract][Full Text] [Related]
19. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.
Yoshioka Y; Nose T; Yoshida K; Oh RJ; Yamada Y; Tanaka E; Yamazaki H; Inoue T; Inoue T
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):213-20. PubMed ID: 12694841
[TBL] [Abstract][Full Text] [Related]
20. Influence of prostate volume on dosimetry results in real-time 125I seed implantation.
McNeely LK; Stone NN; Presser J; Chircus JH; Stock RG
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):292-9. PubMed ID: 14697451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
